Choose a country below to begin
- FDA Breakthrough Therapy
- FDA Accelerated Approval
- FDA CPP for Unapproved Products
- FDA Fast Track
- FDA Orphan Designation
- FDA Priority Review
- FDA Real Time Oncology Review-RTOR
- FDA Regenerative Medicine Advanced Therapy Designation
- Limited Population Pathway for Antibacterial and Antifungal Drugs
- Split Real-Time Application Review (STAR) Program
- Coronavirus Treatment Acceleration Program (CTAP)
- Accelerating Rare disease Cures (ARC) Program
- Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program
- Emergency Use Authorization (EUA)
- Emergency Use Authorization for Vaccines to Prevent COVID-19
- Project FrontRunner
- Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program
- Tropical Disease Priority Review Voucher Program
- Generating Antibiotic Incentives Now (GAIN)
- FDA-EMA Parallel Scientific Advice Pilot Program for Complex Generic/Hybrid Products
- Animal Rule Approvals
- USFDA-EMA Mutual Recognition Agreement for GMP Inspections
- Model-Informed Drug Development Paired Meeting Program
- Advanced Manufacturing Technologies Designation Program
- Collaboration on Gene Therapies Global Pilot (CoGenT)
- Biosimilar Regulatory Review and Approval
- Importation Program under Section 804 of the FD&C Act
- Commissioner’s National Priority Voucher (CNPV) Program
- FDA Accelerated Approval
- FDA CPP for Unapproved Products
- FDA Fast Track
- FDA Orphan Designation
- FDA Priority Review
- FDA Real Time Oncology Review-RTOR
- FDA Regenerative Medicine Advanced Therapy Designation
- Limited Population Pathway for Antibacterial and Antifungal Drugs
- Split Real-Time Application Review (STAR) Program
- Coronavirus Treatment Acceleration Program (CTAP)
- Accelerating Rare disease Cures (ARC) Program
- Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program
- Emergency Use Authorization (EUA)
- Emergency Use Authorization for Vaccines to Prevent COVID-19
- Project FrontRunner
- Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program
- Tropical Disease Priority Review Voucher Program
- Generating Antibiotic Incentives Now (GAIN)
- FDA-EMA Parallel Scientific Advice Pilot Program for Complex Generic/Hybrid Products
- Animal Rule Approvals
- USFDA-EMA Mutual Recognition Agreement for GMP Inspections
- Model-Informed Drug Development Paired Meeting Program
- Advanced Manufacturing Technologies Designation Program
- Collaboration on Gene Therapies Global Pilot (CoGenT)
- Biosimilar Regulatory Review and Approval
- Importation Program under Section 804 of the FD&C Act
- Commissioner’s National Priority Voucher (CNPV) Program